Aberdeen Group plc Makes New Investment in InspireMD, Inc. $NSPR

Aberdeen Group plc bought a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 2,481,117 shares of the company’s stock, valued at approximately $5,979,000. Aberdeen Group plc owned approximately 5.95% of InspireMD as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NSPR. Soleus Capital Management L.P. boosted its position in shares of InspireMD by 99.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 1,886,207 shares of the company’s stock valued at $4,282,000 after purchasing an additional 940,831 shares in the last quarter. Rosalind Advisors Inc. lifted its stake in InspireMD by 0.6% during the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company’s stock valued at $5,196,000 after purchasing an additional 14,109 shares during the last quarter. Creative Planning bought a new stake in InspireMD during the second quarter worth approximately $44,000. Affiance Financial LLC grew its position in InspireMD by 32.4% in the third quarter. Affiance Financial LLC now owns 250,370 shares of the company’s stock worth $603,000 after buying an additional 61,248 shares during the last quarter. Finally, Vestia Personal Wealth Advisors increased its holdings in shares of InspireMD by 135.7% in the third quarter. Vestia Personal Wealth Advisors now owns 42,425 shares of the company’s stock valued at $102,000 after buying an additional 24,425 shares in the last quarter. 44.78% of the stock is currently owned by institutional investors.

InspireMD Trading Up 4.0%

Shares of InspireMD stock opened at $1.81 on Friday. InspireMD, Inc. has a 1 year low of $1.51 and a 1 year high of $3.80. The company has a market cap of $76.69 million, a P/E ratio of -2.41 and a beta of 0.93. The stock has a 50-day moving average price of $1.77 and a 200 day moving average price of $2.08.

Insider Buying and Selling

In related news, insider Shane Thomas Gleason sold 17,593 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $1.62, for a total value of $28,500.66. Following the transaction, the insider owned 1,174,664 shares in the company, valued at approximately $1,902,955.68. This represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 61,194 shares of company stock valued at $99,188 in the last 90 days. Corporate insiders own 34.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Maxim Group assumed coverage on InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $5.00.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.